Comparator: pregabalin + Comparator: Placebo (unspecified)
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neuralgia, Postherpetic
Conditions
Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
Trial Timeline
Dec 1, 2007 → Sep 1, 2008
NCT ID
NCT00570310About Comparator: pregabalin + Comparator: Placebo (unspecified)
Comparator: pregabalin + Comparator: Placebo (unspecified) is a phase 1 stage product being developed by Merck for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT00570310. Target conditions include Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00570310 | Phase 1 | Completed |
Competing Products
20 competing products in Neuralgia, Postherpetic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 23 |
| QUTENZA | Astellas Pharma | Approved | 85 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 52 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2/3 | 65 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Galcanezumab | Eli Lilly | Approved | 85 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 52 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| Cetuximab + Placebo | Merck | Phase 2 | 52 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| EMA401 + Placebo | Novartis | Phase 2 | 52 |
| pregabalin | Pfizer | Approved | 84 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| 2-weeks placebo then gabapentin + 1-week placebo then gabapentin | Pfizer | Pre-clinical | 22 |